# argenx SE (ARGX)

> Source: Nexqual · https://nexqual.com/ARGX · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, argenx SE (ARGX), nexqual.com/ARGX" · informational, not investment advice.

**Price:** USD 875.76 (-1.61% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 890.05 · day 853.28–897.27 · 52w 661.85–1,072.75 · market cap $55.1B · NMS

## Key facts
- Analysts: Buy (mean 1.84 on a 1–5 scale) (25 analysts), mean target USD 1,150.91 (range 861–1,356).
- Total return with dividends: 1Y +7.8% vs S&P 500 +14.9%; 5Y +198.7% vs S&P 500 +80.3%.
- Next earnings: 2026-10-22, EPS estimate USD 7.32, revenue estimate $1.89B.

## Analysts
Consensus Buy (mean 1.84 on a 1–5 scale), 25 analysts; mean target USD 1,150.91 (low 861, high 1,356).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-20 | RBC Capital | Target lowered | Outperform | $1100 → $1025 |
| 2026-10-14 | Wells Fargo | Target raised | Overweight | $1355 → $1356 |
| 2026-10-12 | Oppenheimer | Target lowered | Outperform | $1100 → $1038 |
| 2026-10-09 | Evercore ISI Group | Target lowered | Outperform | $1175 → $1078 |
| 2026-10-09 | Baird | Target lowered | Neutral | $932 → $823 |
| 2026-09-08 | Wedbush | Reiterated | Outperform | $1150 |
| 2026-09-03 | Wedbush | Reiterated | Outperform | $1150 |
| 2026-08-31 | Morgan Stanley | Target raised | Overweight | $1230 → $1250 |
| 2026-08-26 | UBS | Upgrade | Neutral → Buy | $960 → $1400 |
| 2026-08-26 | Wells Fargo | Target raised | Overweight | $1350 → $1415 |
| 2026-08-18 | Truist Securities | Target raised | Buy | $1030 → $1095 |
| 2026-08-18 | Morgan Stanley | Target raised | Overweight | $1200 → $1230 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +7.8% | +198.7% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +7.9% | +24.4% |
| Volatility (annualized) | 36.9% | 37.9% |
| Max drawdown | -28.6% (Nov 2025→Mar 2026) | -34.3% (Jul 2023→Apr 2024) |

## Peers (Biotechnology)
ONC (BeOne Medicines Ltd.) USD 382.27 -1.08% · MRNA (Moderna, Inc.) USD 202.63 -17.57% · RVMD (Revolution Medicines, Inc.) USD 187.69 -3.39% · REGN (Regeneron Pharmaceuticals, Inc.) USD 819.09 +1.67% · RPRX (Royalty Pharma plc) USD 63.75 +2.57% · ALNY (Alnylam Pharmaceuticals, Inc.) USD 227.28 +0.97%

## More
Full page: https://nexqual.com/ARGX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in ARGX's own 20-F filed 2026-03-19 (https://www.sec.gov/Archives/edgar/data/1697862/000169786226000032/argx-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | AbbVie (ABBV) | "currently have collaborative research relationships with various pharmaceutical companies such as AbbVie, Zai Lab and" |
| Partner | HALOZYME THERAPEUTICS, INC. (HALO) | "In February 2019, the Company entered into a global collaboration and license agreement with Halozyme Therapeutics," |
| Partner | Lonza | "The Company's commercial supply is manufactured in collaboration with Lonza and Fujifilm." |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-12-31) | $7.32 | $8.14 | -10.1% | $1.89B | 2 |
| Next quarter (ends 2027-03-31) | $6.49 | $7.93 | -18.2% | $1.85B | 1 |
| Current fiscal year (ends 2026-12-31) | $28.27 | $27.83 | +1.6% | $6.37B | 4 |
| Next fiscal year (ends 2027-12-31) | $33.31 | $39.05 | -14.7% | $7.77B | 4 |

## Options: expected move (Cboe, 15-min delayed)

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 34.6% | ±7.8% |
| 2026-12-18 | 56 | 39.0% | ±12.3% |
| 2027-01-15 | 84 | 39.1% | ±15.0% |
| 2027-02-19 | 119 | 38.6% | ±17.6% |
| 2027-03-19 | 147 | 38.9% | ±19.7% |
| 2027-05-21 | 210 | 39.4% | ±23.9% |